Log in
NASDAQ:EYEG

EyeGate Pharmaceuticals Stock Forecast, Price & News

$3.82
+0.03 (+0.79 %)
(As of 10/23/2020 04:49 PM ET)
Add
Compare
Today's Range
$3.76
Now: $3.82▼
$3.84
50-Day Range
$3.60
MA: $3.79▼
$3.95
52-Week Range
$3.11
Now: $3.82▼
$12.89
Volume14,930 shs
Average Volume106,447 shs
Market Capitalization$17.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Read More
EyeGate Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.77 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEG
Previous Symbol
CUSIPN/A
CIK1372514
Webwww.eyegatepharma.com
Phone781-788-8869
Employees10

Debt

Debt-to-Equity Ratio0.04
Current Ratio6.37
Quick Ratio6.37

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.69 million
Price / Sales6.57
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.64 per share
Price / Book2.33

Profitability

EPS (Most Recent Fiscal Year)($2.23)
Net Income$-7,100,000.00
Net MarginsN/A
Return on Equity-135.39%
Return on Assets-93.03%

Miscellaneous

Outstanding Shares4,627,000
Market Cap$17.68 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$3.82
+0.03 (+0.79 %)
(As of 10/23/2020 04:49 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











EyeGate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

How has EyeGate Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

EyeGate Pharmaceuticals' stock was trading at $5.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EYEG shares have decreased by 24.1% and is now trading at $3.82.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of EyeGate Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyeGate Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for EyeGate Pharmaceuticals.

When is EyeGate Pharmaceuticals' next earnings date?

EyeGate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for EyeGate Pharmaceuticals.

How were EyeGate Pharmaceuticals' earnings last quarter?

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) announced its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.05.
View EyeGate Pharmaceuticals' earnings history.

What price target have analysts set for EYEG?

2 analysts have issued twelve-month price targets for EyeGate Pharmaceuticals' shares. Their forecasts range from $9.50 to $12.00. On average, they expect EyeGate Pharmaceuticals' stock price to reach $10.75 in the next year. This suggests a possible upside of 181.4% from the stock's current price.
View analysts' price targets for EyeGate Pharmaceuticals.

Are investors shorting EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totaling 27,000 shares, a decline of 18.7% from the August 31st total of 33,200 shares. Based on an average daily volume of 201,500 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.6% of the company's stock are sold short.
View EyeGate Pharmaceuticals' Short Interest.

Who are some of EyeGate Pharmaceuticals' key competitors?

Some companies that are related to EyeGate Pharmaceuticals include IMMUTEP LTD/S (IMMP), Satsuma Pharmaceuticals (STSA), Novan (NOVN), Galmed Pharmaceuticals (GLMD), Aptorum Group (APM), Infinity Pharmaceuticals (INFI), Aridis Pharmaceuticals (ARDS), Synlogic (SYBX), Addex Therapeutics (ADXN), Rockwell Medical (RMTI), CannTrust (CNTTF), Clearside Biomedical (CLSD), Elite Pharmaceuticals (ELTP), Mereo BioPharma Group (MREO) and Conatus Pharmaceuticals (CNAT).
View all competitors.

What other stocks do shareholders of EyeGate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EyeGate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Novavax (NVAX), SCYNEXIS (SCYX), Trevena (TRVN), Exelixis (EXEL) and Gilead Sciences (GILD).

Who are EyeGate Pharmaceuticals' key executives?

EyeGate Pharmaceuticals' management team includes the following people:
  • Mr. Stephen From, Pres, CEO & Director (Age 57, Pay $506.6k)
  • Ms. Sarah Romano, Chief Financial Officer (Age 40, Pay $336.01k)
  • Dr. MaryJane Rafii, Consultant

When did EyeGate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

What is EyeGate Pharmaceuticals' stock symbol?

EyeGate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How do I buy shares of EyeGate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is EyeGate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $3.82.

How big of a company is EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals has a market capitalization of $17.68 million and generates $2.69 million in revenue each year. The specialty pharmaceutical company earns $-7,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. EyeGate Pharmaceuticals employs 10 workers across the globe.

What is EyeGate Pharmaceuticals' official website?

The official website for EyeGate Pharmaceuticals is www.eyegatepharma.com.

How can I contact EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.

This page was last updated on 10/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.